Antibacterials, antimycobacterials and antimycotics for systemic use, part 2

Finnish Institute for Health and Welfare, later referred to as THL or Customer, requested tenders for "Antibacterials, antimycobacterials and antimycotics for systemic use, part 2" to the rescEU Medical -project. The Scope of procurement is described in more detail in to the Call for tenders and its annexes. The procurement is divided in seven (7) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. LOT 1: Ertapenem 1 g (1 g powder for i.v. / vial, ATC J01DH03) LOT 2: Cefiderocol 1 g (1 g powder for i.v. / vial, ATC J01DI04) LOT 3: Clindamycin 150 mg/ml (4 ml per vial/ampoule, ATC J01FF01) LOT 4: Levofloxacin 5 mg/ml (100 ml, i.v. solution, ATC J01MA12) LOT 5: Ceftriaxone natrium 2 g (2 g powder for i.v. / vial, ATC J01DD04) LOT 6: Fluconazole 2 mg/ml (100 ml, i.v. solution, ATC J02AC01) LOT 7: Rifampicin 300 mg or 600 mg (tablet/capsule, oral, ATC J04AB02) The minimum requirements for the products is described in Annex 1.1 to the Call for tenders. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the Contract has been signed by contracting parties and expires when all contractual duties of the Contract have been performed. Quantity for the products is described in Annex 7 to the Call for tenders (restricted to security classification level IV, TL IV). In addition to the quantity indicated in the Annex 7 to the Call for tenders, the Customer is entitled to purchase 100 % extra to the quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option. Please note that all times given in the Call for tenders refer to local time in Finland. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Description of the rotation Annex 2.1 Quality scoring table Annex 3 Contract Annex 4 Security annex Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Confidentiality commitment Annex 7 Quantity of the Articles (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract and the Call for tenders. The numbering of the Annexes to the Contract is based on the order of precedence applied in the Contract., LOT 1: Ertapenem 1 g (1 g powder for i.v. / vial, ATC J01DH03) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ertapenem 1 g (1 g powder for i.v. / vial, ATC J01DH03) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Ertapenem - Pharmaceutical form: 1 g powder for i.v. / vial The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 (restricted, TL IV) to the Call for tenders. In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 2: Cefiderocol 1 g (1 g powder for i.v. / vial, ATC J01DI04) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Cefiderocol 1 g (1 g powder for i.v. / vial, ATC J01DI04) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Cefiderocol - Pharmaceutical form: 1 g powder for i.v. / vial The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 to the Call for tenders (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 3: Clindamycin 150 mg/ml (4 ml per vial/ampoule, ATC J01FF01) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Clindamycin 150 mg/ml (4 ml per vial/ampoule, ATC J01FF01) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Clindamycin - Strength: 150 mg/ml - Pharmaceutical form: 4 ml i.v., per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 to the Call for tenders (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 4: Levofloxacin 5 mg/ml (100 ml, i.v. solution, ATC J01MA12) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Levofloxacin 5 mg/ml (100 ml, i.v. solution, ATC J01MA12) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Levofloxacin - Strength: 5 mg/ml - Pharmaceutical form: 100ml, i.v. solution, bottle The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 to the Call for tenders (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 5: Ceftriaxone natrium 2 g (2 g powder for i.v. / vial, ATC J01DD04) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ceftriaxone natrium 2 g (2 g powder for i.v. / vial, ATC J01DD04) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Ceftriaxone natrium - Pharmaceutical form: 2 g powder for i.v. / vial The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 (restricted, TL IV) to the Call for tenders. In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 6: Fluconazole 2 mg/ml (100 ml, i.v. solution, ATC J02AC01) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Fluconazole 2 mg/ml (100 ml, i.v. solution, ATC J02AC01) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Fluconazole - Strength: 2 mg/ml - Pharmaceutical form: 100ml, i.v. solution, bottle The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 (restricted, TL IV) to the Call for tenders. In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 7: Rifampicin 300 mg or 600 mg (tablet/capsule, oral, ATC J04AB02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Rifampicin 300 mg or 600 mg (tablet/capsule, oral, ATC J04AB02) - Oral solid dosage forms - Active pharmaceutical ingredient: Rifampicin - Strength: 300 mg or 600 mg - Pharmaceutical form: tablet/capsule The minimum requirements of the Article is described in more detail in Annex 1.1 to the Call for tenders. The delivery schedule for the articles is described in Annex 1 to the Call for tenders. Quantity for the Article is described in Annex 7 (restricted, TL IV) to the Call for tenders. In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article: either of 300 mg or 600 mg tablet/capsule. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.,